| 摘要 |
The present invention relates to human antibodies, for example those directe d to the human IGF-1 receptor (IGF-1R) that are for treatment of cancer, that have one or more selected mutated residues replaced with germline residues. A replaced residue can be a somatic mutation in a framework region.
|
